Back to top
more

Montes Archimedes Acquisition (ROIV)

(Delayed Data from NSDQ)

$11.03 USD

11.03
3,109,699

+0.15 (1.38%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $11.03 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for ROIV

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Roivant Sciences Ltd falls in the month of March.

All items in Millions except Per Share data.

3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Assets          
Cash & Equivalents -99,999 1,677 2,064 2,133 -99,999
Receivables NA 0 0 0 NA
Notes Receivable NA 0 0 0 NA
Inventories NA 0 0 0 NA
Other Current Assets NA 122 82 54 NA
Total Current Assets NA 1,799 2,147 2,187 NA
Net Property & Equipment NA 39 26 15 NA
Investments & Advances NA 304 326 290 NA
Other Non-Current Assets NA 0 0 0 NA
Deferred Charges NA 0 0 0 NA
Intangibles NA 145 0 0 NA
Deposits & Other Assets NA 49 26 36 NA
Total Assets NA 2,390 2,585 2,590 NA
Liabilities & Shareholders Equity 3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Notes Payable NA 0 0 0 NA
Accounts Payable NA 38 35 21 NA
Current Portion Long-Term Debt NA 41 0 0 NA
Current Portion Capital Leases NA 0 0 0 NA
Accrued Expenses NA 167 128 77 NA
Income Taxes Payable NA 0 0 0 NA
Other Current Liabilities NA 15 11 109 NA
Total Current Liabilities NA 272 184 219 NA
Mortgages NA 0 0 0 NA
Deferred Taxes/Income NA 0 14 0 NA
Convertible Debt NA 0 0 0 NA
Long-Term Debt NA 376 210 170 NA
Non-Current Capital Leases NA 0 0 0 NA
Other Non-Current Liabilities NA 81 53 76 NA
Minority Interest (Liabilities) NA 0 22 22 NA
Total Liabilities NA 782 546 550 NA
Shareholders Equity 3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Preferred Stock NA 0 0 0 NA
Common Stock (Par) NA 0 0 0 NA
Capital Surplus NA 4,933 4,422 3,815 NA
Retained Earnings NA -3,773 -2,764 -1,918 NA
Other Equity NA 447 381 143 NA
Treasury Stock NA 0 0 0 NA
Total Shareholder's Equity NA 1,608 2,039 2,040 NA
Total Liabilities & Shareholder's Equity NA 2,390 2,585 2,590 NA
Total Common Equity 0 1,608 2,039 2,040 0
Shares Outstanding 805.80 760.10 694.90 15.00 NA
Book Value Per Share 0.00 2.11 2.93 135.97 0.00

Fiscal Year End for Roivant Sciences Ltd falls in the month of March.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 6,671 1,408 1,434 1,677
Receivables NA 0 0 0 0
Notes Receivable NA 0 0 0 0
Inventories NA 0 0 0 0
Other Current Assets NA 136 143 127 122
Total Current Assets NA 6,807 1,552 1,561 1,799
Net Property & Equipment NA 22 24 36 39
Investments & Advances NA 240 250 296 304
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 150 141 145 145
Deposits & Other Assets NA 47 50 46 49
Total Assets NA 7,313 2,066 2,137 2,390
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 35 44 50 38
Current Portion Long-Term Debt NA 46 49 44 41
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 122 153 119 167
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 31 9 20 15
Total Current Liabilities NA 245 266 245 272
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 403 389 385 376
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 36 121 81
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 728 740 803 782
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 5,390 5,321 4,982 4,933
Retained Earnings NA 727 -4,369 -4,065 -3,773
Other Equity NA 467 374 417 447
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 6,585 1,326 1,334 1,608
Total Liabilities & Shareholder's Equity NA 7,313 2,066 2,137 2,390
Total Common Equity 0 6,585 1,326 1,334 1,608
Shares Outstanding 805.80 804.80 800.70 767.10 760.10
Book Value Per Share 0.00 8.18 1.66 1.74 2.11